Detalhe da pesquisa
1.
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
N Engl J Med
; 384(16): 1491-1502, 2021 04 22.
Artigo
Inglês
| MEDLINE | ID: mdl-33631065
2.
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
JAMA
; 329(1): 39-51, 2023 01 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36525245
3.
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
JAMA
; 329(14): 1183-1196, 2023 04 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37039790
4.
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
JAMA
; 327(13): 1247-1259, 2022 04 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35315874
5.
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
JAMA
; 326(17): 1690-1702, 2021 Nov 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34606578
6.
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
JAMA
; 324(13): 1317-1329, 2020 10 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32876697
7.
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.
Ann Am Thorac Soc
; 17(7): 879-891, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32267771